View of Dose-dense versus 3-weekly ac during neoadjuvant chemoimmunotherapy for early-stage triple-negative breast cancer: GBECAM 0123 – the neo-real study

Return to Article Details Dose-dense versus 3-weekly ac during neoadjuvant chemoimmunotherapy for early-stage triple-negative breast cancer: GBECAM 0123 – the neo-real study Download Download PDF